Yahoo
Shenzhen - Delayed Quote CNY

Daan Gene Co., Ltd. (002030.SZ)

5.18 -0.09 (-1.71%)
At close: October 30 at 3:04:36 PM GMT+8
Chart Range Bar
Loading chart for 002030.SZ
  • Previous Close 5.27
  • Open 5.21
  • Bid 5.18 x --
  • Ask 5.19 x --
  • Day's Range 5.17 - 5.37
  • 52 Week Range 4.80 - 8.20
  • Volume 18,669,173
  • Avg. Volume 24,660,207
  • Market Cap (intraday) 7.27B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -0.53
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date Jun 14, 2024
  • 1y Target Est --

Daan Gene Co., Ltd., together with its subsidiaries, researches and develops, manufactures, and sells clinical test reagents, instruments, and supporting consumables in China. It operates through two segments, Biological Products and Related Business and Financial Business. The company offers PCR testing kits, including hepatitis virus, human papillomavirus (HPV), sexually transmitted infections sexually transmitted infections, human immunodeficiency virus, blood screening, respiratory infections, digestive pathogens, public health, coronavirus disease (COVID-19), tumor marker, pharmacogenomics, nucleic acid extraction, and viral transport medium (VTM) collection kits. It also provides molecular diagnostic instruments comprising PCR detection systems, nucleic acid extraction systems, and sample transfer processing systems. In addition, the company offers immunoassay test kits that include COVID-19 rapid test kits; pathology tests, such as liquid based cytology production and automatic sample transfer machines; and auto biochemistry analyzers. It sells its products under the Daan Gene, Darui Biology, LBP, and Zhongshan Bio-Tech brands. The company was formerly known as Da An Gene Co., Ltd. of Sun Yat-Sen University. Daan Gene Co., Ltd. was incorporated in 1988 and is headquartered in Guangzhou, China.

www.daangene.com

1,506

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

002030.SZ
13.09%
SSE Composite Index (000001.SS)
9.32%

1-Year Return

002030.SZ
18.43%
SSE Composite Index (000001.SS)
9.73%

3-Year Return

002030.SZ
46.85%
SSE Composite Index (000001.SS)
19.11%

5-Year Return

002030.SZ
66.77%
SSE Composite Index (000001.SS)
1.46%

Earnings Trends

View More

Earnings Per Share (Normalized)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY17
Revenue 382.35M
Earnings --
Profit Margin 0.00%

Q4

FY16

Q1

FY17

Q2

FY17

Q3

FY17

0
100M
200M
300M
400M
0.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -95.69%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    -10.23%

  • Revenue (ttm)

    776.43M

  • Net Income Avi to Common (ttm)

    -742.97M

  • Diluted EPS (ttm)

    -0.53

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    --

  • Total Debt/Equity (mrq)

    1.43%

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: